Compare MC & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MC | ELVN |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.2B |
| IPO Year | 2014 | 2020 |
| Metric | MC | ELVN |
|---|---|---|
| Price | $68.13 | $57.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $72.88 | $43.40 |
| AVG Volume (30 Days) | 939.0K | ★ 986.1K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.88% | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 0.75 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $17.22 | N/A |
| P/E Ratio | $91.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.06 | $14.79 |
| 52 Week High | $78.22 | $62.32 |
| Indicator | MC | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 59.86 |
| Support Level | $68.19 | $25.63 |
| Resistance Level | $71.29 | $62.32 |
| Average True Range (ATR) | 2.40 | 2.69 |
| MACD | 0.07 | -0.29 |
| Stochastic Oscillator | 69.46 | 63.03 |
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.